GlassScriptPhysician profile
Jennifer Davis
NPI 1861074775
$5,681.45
in general payments reported to CMS, 2019-2025
40 companies · $1,558 in 2025
The $1,558 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $234 · 2022: $781 · 2023: $900 · 2024: $2,207 · 2025: $1,558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,538 · Education: $128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,537.85 |
| Education | $127.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,877.69 | 2021-2025 | |
| Gilead Sciences, INC. | $831.84 | 2021-2024 | Epclusa |
| Takeda Pharmaceuticals U.S.A., INC. | $351.34 | 2022-2025 | Eohilia, Entyvio, Takhzyro |
| Lilly USA, LLC | $329.13 | 2023-2025 | Omvoh |
| Janssen Biotech, INC. | $285.76 | 2024-2025 | Tremfya, Stelara |
| Intercept Pharmaceuticals, INC. | $171.87 | 2022-2024 | Ocaliva |
| Astrazeneca Pharmaceuticals LP | $150.11 | 2025 | Airsupra, Tezspire |
| Ferring Pharmaceuticals INC. | $147.06 | 2023-2025 | Rebyota, Clenpiq |
| Novartis Pharmaceuticals Corporation | $143.76 | 2025 | |
| Ardelyx, INC. | $139.40 | 2024-2025 | Ibsrela |
| Janssen Scientific Affairs, LLC | $136.80 | 2024 | Remicade, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.30 | 2022-2024 | Xifaxan |
| Glaxosmithkline, LLC. | $103.48 | 2025 | |
| Madrigal Pharmaceuticals | $96.06 | 2024-2025 | Resmetirom, Rezdiffra |
| Genzyme Corporation | $86.66 | 2022-2025 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.